NCKU professor wins 2013 Taiwan BIO Award - CNA
NCKU professor wins 2013 Taiwan BIO Award
Dr. Chang Ming-Shi, a professor of the Department of Biochemistry and Molecular Biology at National Cheng Kung University (NCKU), southern Taiwan, won the 2013 Taiwan Bio Industry Organization Award - Innovation of the Year, recently.
“It is honored to receive the award from the hands of President Ma Ying-Jeou,” said Dr. Chang who is the only winner from the academia.
The ceremony organized by the Taiwan Bio Industry Organization (TBIO) was held, July 18, at TWTC Nangang Exhibition Center, Taipei.
Chang stated that this is a thrilling moment for the domestic biotechnology and her winning the award may inspire more students and professors to devote themselves into the field of biotechnology and biomedicine.
President Ma Ying-Jeou said at the ceremony that his government plans to increase investment in the local biotech industry by more than 25 percent in three years to make Taiwan a global leader in biotech and pharmaceutical development.
He also noted that Taiwan's biotech industry generated total revenues of NT$263 billion last year, increasing nearly 10 percent from the previous year, which resulted in a growth rate higher than any other sectors.
Taiwan's biotech industry has been taking off in recent years, with the country having more than 70 listed biotech companies, whose market capitalization rose from NT$80 billion in 2009 to NT$400 billion in 2012, according to Johnsee Lee, president of TBIO.
“If the research carried out by a professor is failed to solve the problems then the research is not worthwhile to conduct at all,” according to Chang.
She also said that her research has a clear market orientation and is beneficial to the patients.
“I’m very proud of my students,” said Chang who mentioned that she is lucky to have students who are willing to take the challenge and fulfill the commitments.
NCKU research team led by Dr. Ming-Shi Chang had discovered an anti-interleukin-20 (anti-IL-20) antibody, a potential new anti-osteoporosis and anti-rheumatoid arthritis drug, and licensed selected intellectual property and transferred certain technology to Novo Nordisk A/S, a Danish-based pharmaceutical company for a total payment of US$13.3 million in case of a successful completion of the project.
The 2013 Taiwan Bio Industry Organization Award is mainly in recognition of outstanding performance and great potential of biotech companies or academic institutes.
TBIO organize the annual Bio Taiwan conferences and exhibition, the largest gathering of biotechnology industry in Taiwan.
Enditem/
Dr. Chang Ming-Shi, a professor of the Department of Biochemistry and Molecular Biology at National Cheng Kung University (NCKU), southern Taiwan, won the 2013 Taiwan Bio Industry Organization Award - Innovation of the Year, recently.
“It is honored to receive the award from the hands of President Ma Ying-Jeou,” said Dr. Chang who is the only winner from the academia.
The ceremony organized by the Taiwan Bio Industry Organization (TBIO) was held, July 18, at TWTC Nangang Exhibition Center, Taipei.
Chang stated that this is a thrilling moment for the domestic biotechnology and her winning the award may inspire more students and professors to devote themselves into the field of biotechnology and biomedicine.
President Ma Ying-Jeou said at the ceremony that his government plans to increase investment in the local biotech industry by more than 25 percent in three years to make Taiwan a global leader in biotech and pharmaceutical development.
He also noted that Taiwan's biotech industry generated total revenues of NT$263 billion last year, increasing nearly 10 percent from the previous year, which resulted in a growth rate higher than any other sectors.
Taiwan's biotech industry has been taking off in recent years, with the country having more than 70 listed biotech companies, whose market capitalization rose from NT$80 billion in 2009 to NT$400 billion in 2012, according to Johnsee Lee, president of TBIO.
“If the research carried out by a professor is failed to solve the problems then the research is not worthwhile to conduct at all,” according to Chang.
She also said that her research has a clear market orientation and is beneficial to the patients.
“I’m very proud of my students,” said Chang who mentioned that she is lucky to have students who are willing to take the challenge and fulfill the commitments.
NCKU research team led by Dr. Ming-Shi Chang had discovered an anti-interleukin-20 (anti-IL-20) antibody, a potential new anti-osteoporosis and anti-rheumatoid arthritis drug, and licensed selected intellectual property and transferred certain technology to Novo Nordisk A/S, a Danish-based pharmaceutical company for a total payment of US$13.3 million in case of a successful completion of the project.
The 2013 Taiwan Bio Industry Organization Award is mainly in recognition of outstanding performance and great potential of biotech companies or academic institutes.
TBIO organize the annual Bio Taiwan conferences and exhibition, the largest gathering of biotechnology industry in Taiwan.
Enditem/
Click Num:
Share
